Subscribe to Newsletter

Retina

Subspecialties Basic & Translational Research

A Translation Boost for USH

| Sarah Healey | 4 min read

Improving translational models for inherited retinal diseases

Subspecialties Retina

Real ROP Progress

| Sarah Healey | 3 min read

EYLEA: The FDA approved VEGF inhibitor for ROP

Subspecialties Imaging & Diagnostics

Seeing The Difference

| Sponsored by Topcon Healthcare | 4 min read

Two ophthalmologists share how Topcon’s Triton OCT makes a difference in their clinics.

Subspecialties Retina

Looking Beyond Lockdown

| Sarah Healey | 2 min read

Can myopia be reversed?

Subspecialties Retina

When One Becomes Two

| Yang Fei | 7 min read

Two disease pathways identified in AMD

Business & Profession Basic & Translational Research

A Patient-First Approach

| Sally Tucker, Gustavo de Moreas | 6 min read

New research and development for AMD to improve patient quality of life

Subspecialties Retina

Mind the (Retinal Age) Gap

| Sarah Healey | 2 min read

Identifying new biomarkers for kidney failure

Subspecialties COVID-19

A Shared Interest

| Sarah Healey | 2 min read

COVID-19 and AMD share common genetic risk factors

Subspecialties Neuro-ophthalmology

The Next (Re)generation

| Jennifer Arcuri, Sanjoy Bhattacharya | 4 min read

How nerve regeneration through small molecules could restore sight

Subspecialties Basic & Translational Research

Printing for Progress

| Sarah Healey | 2 min read

Improving AMD detection through 3D bioprinted eye tissue

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer element

This new disclaimer element is now part of all brands. It is editable on the start page and will be shown on all pages

Once confirmed we store a cookie to not show the disclaimer again.